Johnson & Johnson Reports Q1 2022 Results

Total sales growth of 5.0% to $23.4 Billion with operational growth of 7.7%* and adjusted operational growth of 7.9%* Earnings per share of $1.93 decreasing 16....

Related Keywords

China ,Ukraine ,Joaquin Duato ,Prnewswire Johnson ,Interventional Solutions ,Exchange Commission ,Skin Health Beauty ,Consumer Health Company ,Consumer Health ,Johnson ,Company Consumer Health ,Chief Executive ,Medical Devices ,Skin Health ,General Surgery ,Advanced Surgery ,Current Reports ,Quarterly Reports ,Annual Reports ,First Cell Therapy ,Refractory Multiple ,Use Every Two Months ,Only Long Acting ,Only Complete Long Acting Injectable ,Streamlined Process ,Submits Marketing Authorisation Application ,European Medicines Agency Seeking Approval ,Bispecific Antibody Teclistamab ,Seeks Approval ,New Indication ,Untreated Mantle Cell ,Presents New Data Demonstrating ,First Line Therapy ,Mutated Metastatic Castration Resistant Prostate ,Johnson Statement ,Nationwide Opioid Settlement ,Puy Synthes Further Reimagines Knee Restoration ,Two New Innovations ,Initiates First Of Its Kind Clinical Study ,Bridge Critical Gaps ,Severe Plaque ,Adjusted Operational Sales ,Operational Sales ,Estimated Reported ,Euro Average Rate ,Private Securities Litigation Reform Act ,New Consumer Health Company ,Annual Report ,Note Regarding Forward Looking ,Consolidated Statement ,Millions Except Per Share Figures ,Millions Except Per Share Data ,Asset Amortization ,Net Earnings ,Medical Device Regulation ,European Medical Devices Directive ,Johnson Amp ,